Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib PET pilot study in early Parkinson's disease
NL-OMON31350Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in Parkinson's disease (PD), sponsored by University Medical Center Groningen. Primary endpoints: Change in [11C]PK11195 PET binding potential, Change in PK11195-derived distribution volume / parametric PET measures and 1 more. Started Sep 2007; status: active, not recruiting.
02
Drugs
celecoxib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON31350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31350.